IPCA Arm To Offload Nine ANDAs To Unichem India For $2.65 Million
Bayshore Pharmaceuticals LLC., a subsidiary of IPCA Laboratories Ltd., is set to sell the rights, titles and interest in the product approvals and goodwill associated with nine of its abbreviated new drug applications to Unichem Laboratories Ltd. for a total sum of $2.65 million, according to an exchange filing on the BSE.
This is to be done through an asset sale agreement, which will be subject to necessary consents or approvals from Unichem India and was approved by the board of directors of the US-based company.
The board also approved the transfer of their US operations in the generic formulations sector to Unichem USA through a slump sale of $10 million, with all associated assets and goodwill and without any debts attached.
The agreement will be entered into on or around Oct. 1, 2024.
It is expected to be completed within 30 days after the signing of the agreement.
The transactions would fall under related party transactions and the transactions have been carried out on an arm's length basis.
Shares of Unichem Laboratories closed 3% higher at Rs 665.35 apiece on the BSE, compared to a 1.49% decline in the BSE Sensex.
-
We May Need Another Tukaram Mundhe To Fight Air Pollution | The Reason Why
Developers may install basic measures such as sprinklers and green nets, resume work, and continue violating rules when this equipment stops working.
-
Extracting Value From Battery Scrap Could Be Challenging For India | The Reason Why
A discarded lithium-ion battery still contains valuable materials such as lithium, nickel and cobalt. These can be recovered and reused. When such batteries are crushed and shredded, they produce a dark powder called black mass.
-
One El Nino, India Can Handle. Two Could Break The Granary
India's grain stocks can absorb one bad year, but a second El Nino could drain the buffer in two to three years, economists say.
-
India's Troika Of Good Luck | Joining The Dots
As Jensen Huang's exit drags Nvidia down, a cooling AI trade and resilient earnings have revived investor interest in India. A likely RBI rate hike looms.
-
Talking Points This Week: Leadership Shock At Nvidia, Earnings Strength, And The Fog Over Hormuz
The Anthropic IPO pricing and first trading day, Nvidia's upcoming earnings, and any fresh signals from Iran will set the tone for the following week.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.